Report error Found 122 Enz. Inhib. hit(s) with Target = 'Transient receptor potential cation channel subfamily M member 5'
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataIC50: 600nMAssay Description:Antagonist activity at TRPM5 (unknown origin)More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataIC50: 600nMAssay Description:Antagonist activity at TRPM5 (unknown origin)More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataIC50: <3.98E+4nMAssay Description:Blocking of human TRPM5 expressed in HEK293 cells by FLIPR membrane potential/summary (Abse5) assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <5.01E+4nMAssay Description:Induction of human TRPM5 opening expressed in HEK293 cells by FLIPR membrane potential/summary (Abse5) assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 4.68E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 331nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.29E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 2.51E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 5.01E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 5.13E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 3.02E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 6.03E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 5.25E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.35E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.62E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 5.13E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 457nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 5.25E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.91E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 89nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 490nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 575nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 4.68E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 158nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 447nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 158nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 5.13E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 468nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 7.59E+3nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 832nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 5(Human)
Turning Point Therapeutics
Curated by ChEMBL
Turning Point Therapeutics
Curated by ChEMBL
Affinity DataEC50: 39nMAssay Description:Agonist activity at human TRPM5 expressed in CHO-K1 cells maintained at 80 mV final holding potential by syncroPatch assayMore data for this Ligand-Target Pair
![](/img/powered_by_small.gif)